- Home
- VMD vs PVLA Comparison
VMD vs PVLA Comparison
Compare VMD & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- PVLA
- Stock Information
- Founded
- VMD 2006
- PVLA 2015
- Country
- VMD United States
- PVLA United States
- Employees
- VMD N/A
- PVLA N/A
- Industry
- VMD
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- PVLA Health Care
- Exchange
- VMD Nasdaq
- PVLA Nasdaq
- Market Cap
- VMD 279.4M
- PVLA 280.4M
- IPO Year
- VMD N/A
- PVLA N/A
- Fundamental
- Price
- VMD $6.32
- PVLA $22.77
- Analyst Decision
- VMD
- PVLA Strong Buy
- Analyst Count
- VMD 0
- PVLA 7
- Target Price
- VMD N/A
- PVLA $44.43
- AVG Volume (30 Days)
- VMD 152.8K
- PVLA 82.1K
- Earning Date
- VMD 05-07-2025
- PVLA 05-15-2025
- Dividend Yield
- VMD N/A
- PVLA N/A
- EPS Growth
- VMD 19.95
- PVLA N/A
- EPS
- VMD 0.30
- PVLA N/A
- Revenue
- VMD $232,793,000.00
- PVLA N/A
- Revenue This Year
- VMD $17.10
- PVLA N/A
- Revenue Next Year
- VMD $10.77
- PVLA N/A
- P/E Ratio
- VMD $20.70
- PVLA N/A
- Revenue Growth
- VMD 19.97
- PVLA N/A
- 52 Week Low
- VMD $6.21
- PVLA $6.20
- 52 Week High
- VMD $9.81
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- VMD 32.39
- PVLA N/A
- Support Level
- VMD $6.80
- PVLA N/A
- Resistance Level
- VMD $7.58
- PVLA N/A
- Average True Range (ATR)
- VMD 0.32
- PVLA 0.00
- MACD
- VMD -0.03
- PVLA 0.00
- Stochastic Oscillator
- VMD 12.80
- PVLA 0.00
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.